Emergent BioSolutions Inc. (EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised a contract option valued at $11.6 million over 12 months under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S. Strategic National Stockpile. VIGIV is a therapeutic licensed by the U.S. Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination. The contract option will require Emergent to conduct manufacturing runs and additional activities in support of maintaining FDA licensure of VIGIV.